Clinical Trials Logo

Cryptococcosis clinical trials

View clinical trials related to Cryptococcosis.

Filter by:

NCT ID: NCT05707156 Completed - Candidiasis Clinical Trials

Prospective Observational Study on the Incidence of Opportunistic Fungal Infections

Start date: July 5, 2023
Phase:
Study type: Observational

Corticosteroids exposure is a common risk factor for invasive fungal infections. Systemic corticosteroid therapy treats several medical conditions, including rejection in solid organ transplant recipients, malignancy, and autoimmune or inflammatory diseases. Corticosteroid exposure is a well-known risk factor for developing PJP. Still, it remains unclear how prior corticosteroid exposure influences the presentation, severity, and mortality of opportunistic fungal infections. The investigators aim to prospectively characterize the corticosteroid use as a dose response to inform risk of invasive fungal infections.

NCT ID: NCT04554875 Recruiting - Lung Adenocarcinoma Clinical Trials

Derivation and Validation of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules

Start date: January 1, 2019
Phase:
Study type: Observational

Pulmonary cryptococcosis often manifests as isolated or multiple nodules, easily mimicking lung cancer clinically and radiologically, which ascribes the poor sensitivity of Cryptococcus culture and rarely positive of Cryptococcal antigen test in the absence of disseminated disease. Therefore, the aim of this study was to develop a predictive scoring system from the perspective of available clinical indicators, to differentiate cryptococcosis from adenocarcinoma in pulmonary nodules, which might be beneficial for the delicacy management of pulmonary nodules.

NCT ID: NCT04033718 Recruiting - Tuberculosis Clinical Trials

Inpatient Package to Reduce HIV and AIDS-related Death in Zambia

IPADZ
Start date: October 1, 2021
Phase: N/A
Study type: Interventional

Early post-discharge mortality is high among HIV-infected Zambians admitted to the hospital. Likely this is in part due to missed opportunities to identify lethal coinfections and optimize HIV care during admission (and before discharge). In this study the investigators will develop and pilot a new approach to inpatient HIV care that follows international guidelines for management of advanced HIV disease.

NCT ID: NCT03993093 Completed - HIV Infections Clinical Trials

Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre

ADC
Start date: June 1, 2019
Phase:
Study type: Observational

HIV patients are likely to suffer from opportunistic infections, in absence of highly active retroviral therapy. This happens due to lack of awareness of HIV status among patients or unresponsive to anti retroviral drugs. This study is for the prevalence of AIDS defining OIs among treatment naive HIV patients.

NCT ID: NCT03267407 Active, not recruiting - HIV/AIDS Clinical Trials

Vietnam Cryptococcal Retention in Care Study - Version 2.1

Start date: August 14, 2015
Phase: N/A
Study type: Observational

This is a multicenter prospective cohort evaluation of the implementation of a cryptococcal antigen (CrAg) screening program at selected outpatient HIV clinics (OPCs) and network laboratories in Vietnam.

NCT ID: NCT03002012 Terminated - Cryptococcosis Clinical Trials

Cryptococcal Antigen Screening Plus Sertraline

C-ASSERT
Start date: November 15, 2017
Phase: Phase 3
Study type: Interventional

Cryptococcal meningitis or "Crypto" is a life threatening fungal infection around the brain that requires hospitalization for treatment for 14 days and then continued therapy. Crypto causes 15-20% of HIV/AIDS-related deaths worldwide. However, this infection can be detected before one develops symptoms and becomes ill. People can be screened for infection by a blood test to detect "cryptococcal antigen," (called CrAg), which is part of the fungus, in blood. The World Health Organization and over 22 countries worldwide recommend CrAg screening of all persons with advanced AIDS entering or re-entering into HIV care. However, it is not known how best to treat people with cryptococcal antigen in their blood, who don't otherwise yet have symptoms of infection around their brain. If no treatment is given, almost all people will develop infection of the brain and/or die. International guidelines suggest using both HIV medicines and an anti-fungal medicine, called fluconazole, to treat this early infection. However, despite this treatment approximately 1 in 4 people may get sick and/or die. Researchers have recently discovered another medicine that may work against the Cryptococcus fungus. This medicine is called Sertraline, and it is actually a medicine that has been used for more than 25 years to treat depression (sadness). Sertraline is one of the most commonly used medicines worldwide. The purpose of this research clinical trial is to determine if standard fluconazole antifungal therapy plus a high dose of Sertraline, will be better than standard fluconazole therapy alone for treating early disseminated cryptococcal infection in persons who are asymptomatic and do not yet have infection of the brain (i.e. meningitis). This study seeks to test if Sertraline will improve survival through 6-months. Prior studies have shown that >90% of those who survive 6-months will survive >5 years.

NCT ID: NCT02503449 Enrolling by invitation - Cryptococcosis Clinical Trials

Clinical Trial of Pulmonary Cryptococcosis in China

MCTOPCIC
Start date: December 2014
Phase: N/A
Study type: Observational [Patient Registry]

The purpose of the study:1.Improve the understanding of the risk factors of pulmonary cryptococcosis;2.Improve the awareness of pulmonary cryptococcosis clinical and imaging manifestations;3.Grasp pulmonary cryptococcosis patients of clinical and imaging manifestations in different conditions;4.Learn about antibacterial activity of antifungal drugs for cryptococcosis in China.

NCT ID: NCT02454569 Recruiting - HIV Clinical Trials

Vicente Ferrer HIV Cohort Study

VFHCS
Start date: September 2009
Phase:
Study type: Observational [Patient Registry]

The VFHCS is a long-term prospective cohort study of HIV infected patients from a resource-poor rural setting in India. The aim of the study is to use data collected from routine clinical care in order to describe the epidemiology of HIV and its related conditions in the investigators area, and to study the effectiveness of health interventions in a "real-world" setting (implementation and operational research).

NCT ID: NCT01656382 Withdrawn - Clinical trials for Invasive Cryptococcosis

Safety, Efficacy, and Pharmacokinetics of Amphotericin B Lipid Complex

Start date: January 2007
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine if initial therapy with ABLC at 10/mg/kg/d for 7 days are at least effective as ABLC at 5.0 mg/kg/d X 14 days as induction treatment of patients with disseminated cryptococcosis and HIV.

NCT ID: NCT01535469 Completed - Clinical trials for Cryptococcal Meningitis

Operational Research for Cryptococcal Antigen Screening

ORCAS
Start date: July 1, 2012
Phase: Phase 4
Study type: Interventional

This will be a stepped wedge randomized trial design to evaluate the implementation of cryptococcal antigen (CRAG) screening and preemptive anti-fungal therapy of HIV-infected persons entering antiretroviral therapy (ART) outpatient treatment in Uganda. Those who are ART eligible with a CD4≤100 cells/mcL will have a serum/plasma CRAG performed by lateral flow assay. Those who are CRAG-positive and asymptomatic will be treated with high dose fluconazole. After 6 months survival with retention-in-care will be compared between those who are CRAG+ and CRAG negative